drugset / Trial / NCT00829868

Zaleplon 10 mg Capsules Under Non-Fasting Conditions

NCT00829868

Phase 1 Completed 42 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the relative bioavailability of zaleplon 10 mg capsules(manufactured and distributed by TEVA Pharmaceuticals USA) with that of SONATA® 10mg capsules (Wyeth-Ayerst Pharmaceuticals) in healthy, non-smoking, adult subjects under non-fasting conditions.

Timeline

Start
2004-02
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Zaleplon Small molecule 10 mg

Indications

No indication recorded.